Canopy Growth Faces Market Struggles with Stock Price at $2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: NASDAQ.COM
- Poor Market Performance: Canopy Growth has struggled in the Canadian market, where despite being a leading grower, it faces slow revenue growth and ongoing net losses due to legal and regulatory challenges.
- Intensifying Competition: The company faces significant pressure from competitors in Canada, and while it has operations in several countries, its overall prospects remain uncertain.
- U.S. Market Opportunities: Although there is potential for improvement in the U.S. market due to an executive order signed by President Trump, federal illegality still hampers operations, making interstate commerce illegal and increasing operational costs.
- Investment Risk Warning: Despite Canopy Growth's stock price being as low as $2, analysts suggest that its prospects in a highly volatile market are poor, advising investors to consider other stocks with greater potential.
Analyst Views on CGC
Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is 3.78 USD with a low forecast of 1.80 USD and a high forecast of 5.76 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.190
Low
1.80
Averages
3.78
High
5.76
Current: 1.190
Low
1.80
Averages
3.78
High
5.76
About CGC
Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
